Management of Anticoagulation in Patients with GI Bleeding

Initial Management During Active Bleeding

The American Gastroenterological Association recommends withholding oral anticoagulants immediately upon presentation with GI bleeding and correcting coagulopathy according to the severity of hemorrhage and the patient's thrombotic risk 1, 2
For patients on warfarin with hemodynamic instability, the American College of Cardiology recommends administering intravenous vitamin K and four-factor prothrombin complex concentrate (PCC); if PCC is unavailable, use fresh frozen plasma 1, 3
For patients on direct oral anticoagulants (DOACs) with hemodynamic instability, the European Society of Cardiology considers specific reversal agents: idarucizumab for dabigatran and andexanet alfa for anti-factor Xa inhibitors; if unavailable, consider four-factor PCC 1, 4
Correction of coagulopathy should not delay endoscopy or radiological intervention, as recommended by the American Society for Gastrointestinal Endoscopy 1, 2

The American Heart Association identifies mechanical heart valves (especially mitral position) as high thrombotic risk patients 5
Atrial fibrillation with prosthetic heart valve or mitral stenosis is also considered high risk by the European Heart Rhythm Association 5
Recent venous thromboembolism (<3 months) is a high-risk condition, according to the American College of Chest Physicians 5

Atrial fibrillation without valvular heart disease is considered low risk by the American College of Cardiology 5
Venous thromboembolism >3 months ago is also considered low risk, as recommended by the American Society of Hematology 1, 5

The European Society of Cardiology recommends resuming anticoagulation earlier, preferably within 3 days of achieving hemostasis 1, 2
Bridging with low molecular weight heparin at 48 hours after hemostasis is achieved may be considered, according to the American College of Chest Physicians 5

The American Gastroenterological Association recommends resuming anticoagulation after 7 days of anticoagulant interruption 1, 2

The American College of Cardiology notes that anticoagulant effect persists for 3-5 days after discontinuation 1
When restarting, monitor INR closely to achieve therapeutic range, as recommended by the American Society for Clinical Pathology 6
Warfarin may be preferred over DOACs in patients at high risk of rebleeding due to more effective and rapid reversal options, according to the European Society of Cardiology 6

The American Heart Association recommends interrupting DOAC therapy at presentation with GI bleeding 6
DOACs have shorter half-lives but may be prolonged in renal failure, particularly dabigatran, as noted by the European Renal Association 6
When restarting DOACs, be aware that full anticoagulant activity is established within 3 hours, according to the American College of Clinical Pharmacy 6

For patients on aspirin monotherapy for secondary prevention, the American College of Cardiology recommends continuing aspirin if possible, as studies show reduction in all-cause mortality despite slightly higher bleeding rates 1, 7
If aspirin is stopped, reintroduce as soon as hemostasis is achieved, as recommended by the American Heart Association 7

The American Gastroenterological Association recommends that all hospitals have a GI bleeding lead and agreed pathways for managing acute GI bleeding 6
Liaison with a consultant interventional cardiologist should occur in emergency settings, especially for patients with recent coronary stents, as recommended by the American College of Cardiology 2, 7
Always have a plan for consideration of restarting antithrombotic therapy in all patients presenting with GI hemorrhage, according to the European Society of Cardiology 1, 2

For patients with low thrombotic risk, the American College of Cardiology recommends restarting anticoagulation at 7 days after the GI bleed, as this timing reduces thromboembolic events and mortality without increasing rebleeding rates, based on a large retrospective study 8, 9
High thrombotic risk patients, including those with a prosthetic metal heart valve in mitral position, should consider low molecular weight heparin at 48 hours after achieving hemostasis, according to the British Society of Gastroenterology 8, 10
The British Society of Gastroenterology acknowledges that restarting Direct Oral Anticoagulants (DOACs) at a maximum of 7 days after hemorrhage for most patients is based on weak recommendation and very low quality evidence, but this timing balances thrombotic and bleeding risks 8, 9
For high thrombotic risk patients on DOACs, consider earlier resumption within 3 days after achieving hemostasis, with potential bridging using low molecular weight heparin at 48 hours, although this is not strongly evidence-based 8, 10
Aspirin for secondary prevention should not be routinely stopped, and if stopped, should be restarted as soon as hemostasis is achieved, as recommended by the American Heart Association 8, 11
P2Y12 receptor antagonists, such as clopidogrel, should be reinstated within 5 days maximum due to high thrombosis risk after this timeframe, according to the American College of Cardiology 8, 10

Watch for signs of recurrent bleeding closely in the first 5 days after resuming anticoagulation, as most rebleeding occurs within this window, as recommended by the British Society of Gastroenterology 10